Biohaven Therapeutics Ltd.

This study tests a new medication, BHV-7000, for people with focal epilepsy that hasn't improved with other treatments. About 390 adults aged 18-75 will receive either the drug or a placebo to see if it safely reduces seizure frequency. The goal is to better control seizures, not…

This study tests whether BHV-8000 can slow the worsening of daily motor skills in people recently diagnosed with Parkinson's disease. About 550 adults aged 40-85 with early Parkinson's will receive either the drug or a placebo. The main goal is to see how long it takes for sympto…

This early-stage study tests whether a new drug called BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 adults with confirmed IgA nephropathy will receive the drug and be monitored for side effects. The goal is to gather safety data, not …

This study tests a new drug called BHV-1510, alone or with another cancer drug (cemiplimab), in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. About 500 adults with incur…

This early-phase study tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

This early-stage study tests whether BHV-1300 is safe for people with Graves' disease, a condition where the immune system attacks the thyroid. Researchers will also look at how the drug affects certain markers of the disease. About 15 adults with confirmed Graves' disease will t…

This study tests whether BHV-7000 can safely reduce seizure frequency in adults with focal epilepsy that hasn't responded to other treatments. About 390 participants will receive either one of two doses of the drug or a placebo, and researchers will compare seizure counts over 8 …